Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more weight and keep it off.
The U.S. Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo Nordisk’s semaglutide. Previously, the highest approved dose of the drug, taken as a weekly shot, was 2.4 milligrams.
The new dose received accelerated review through the FDA’s ultra-fast drug review program. The approval was granted 54 days after the request for review was approved, the agency said in a statement.
The new dosage will be available in April at pharmacies in the U.S., with a price to be announced then, according to the company.
European drug regulators approved the higher-dose version of Wegovy in February.
